ArticleCancers2021

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis.

Michelle L Tas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.